- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00918658
Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
Collection of Bone Marrow and Peripheral Blood for Testing of Notch-induced Natural Killer Cell Activity
RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors find better ways to treat the cancer.
PURPOSE: This research study is looking at natural killer cells in bone marrow and blood samples from patients with hematologic cancer and from patients who do not have cancer.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- To collect normal and malignant cells in bone marrow and peripheral blood samples from patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in cytotoxicity assays.
- To collect information about HLA type and immunophenotype of malignant cells as determined by clinical flow cytometry.
OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44106-5065
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
DISEASE CHARACTERISTICS:
Meets one of the following criteria:
- No evidence of malignancy
Diagnosis of one of the following:
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Chronic myelogenous leukemia
- Multiple myeloma
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Patients with hematologic cancer
Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma
|
All specimens will be collected using the Pathology Residual Tissue Procurement.
Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells.
Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
|
Patients without cancer
Patients who do not have cancer.
|
All specimens will be collected using the Pathology Residual Tissue Procurement.
Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells.
Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Collection of normal and malignant cells to use as target cells in cytotoxicity assays
Tidsram: We anticipate collecting approximately 30 samples in total, over a 1-2 year period.
|
We anticipate collecting approximately 30 samples in total, over a 1-2 year period.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Rose Beck, MD, PhD, Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Hematologiska sjukdomar
- Hemorragiska störningar
- Hemostatiska störningar
- Paraproteinemier
- Blodproteinstörningar
- Multipelt myelom
- Neoplasmer, Plasmacell
- Leukemi
- Plasmacytom
Andra studie-ID-nummer
- CASE2Z08 (Annan identifierare: Case Comprehensive Cancer Center)
- P30CA043703 (U.S.S. NIH-anslag/kontrakt)
- CASE-2Z08-CC502 (Annan identifierare: Cancer Center IRB)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Leukemi
-
Massachusetts General HospitalCelgene CorporationAvslutadAkut myelogen leukemi | Akut myeloid leukemi (AML) | Akut myelocytisk leukemi | Akut granulocytisk leukemi | Akut icke-lymfocytisk leukemiFörenta staterna
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for...RekryteringRefraktär leukemi | Återfallande leukemi | Akut myeloid leukemi, barndomKina
-
GlaxoSmithKlineAvslutadLeukemi, Myelocytisk, AkutFörenta staterna, Australien, Kanada
-
Hybrigenics CorporationOkändAkut myelogen leukemiFörenta staterna, Frankrike
-
Betta Pharmaceuticals Co., Ltd.Har inte rekryterat ännuAkut Myeloid Leukemi LeukemiKina
-
Beijing Boren HospitalRekryteringAkut myeloid leukemi | Refraktär Akut Myeloid Leukemi | Återfall leukemiKina
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationAktiv, inte rekryterandeAkut myelogen leukemiFörenta staterna
-
Massachusetts General HospitalAvslutad
-
Sidney Kimmel Comprehensive Cancer Center at Johns...AvslutadAkut lymfoblastisk leukemi | Akut myelogen leukemi (AML) | Akut lymfatisk leukemi (ALL) | Akut promyelocytisk leukemi (APL)Förenta staterna
-
Kinex Pharmaceuticals Inc.AvslutadAkut myelogen leukemiFörenta staterna